The export licence will allow Medlab to undertake more formal overseas trade conversations with confidence in the knowledge that the company can now supply legally overseas.
Medlab has developed two cannabis-based medicines, NanaBis™ and NanaBidial™, which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).
NanaBis™ has a 1:1 ratio of CBD:THC and NanaBidial™ has a 18:2 ratio of CBD:THC.
Medlab also has a patented delivery platform called NanoCelle™ which delivers medicine in a tiny particle form in a spray into the mouth.
Recently Medlab received preliminary results from the University of Sydney’s Nano Institute, School of Pharmacy validating the science behind the NanoCelle™ delivery platform.